Plaintiffs attorneys suing over the breast cancer drug Taxotere want a federal judge to sanction defendant Sanofi-Aventis U.S. LLC for filing a motion filled with “unfounded accusations” that are “indecent and vexatious” in an attempt to get information on outside funding for the litigation.
The motion, they wrote in a Tuesday filing, is “an unfounded and unseemly attempt to smear both breast cancer survivors” and their lawyers “based entirely on innuendo that is pure McCarthyism.” “Sanofi has not even a scintilla of evidence that plaintiffs’ attorneys are giving up control of their clients’ cases to anyone; they are not,” wrote co-lead plaintiffs attorneys Christopher Coffin, a partner at Pendley Baudin & Coffin in New Orleans, and Karen Barth Menzies, a Los Angeles partner at Girard Gibbs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
